Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Combining Procapil with minoxidil improves hair growth in men with hair loss.

This study found that the TrichoScan effectively measures hair growth changes, showing significant increases in hair counts and thickness in men with androgenetic alopecia after 6 months of using 5% minoxidil solution.

This study reports that a new minoxidil and epigallocatechin gallate co-loaded ionic liquids system showed superior efficacy in promoting hair regrowth in a mouse model of androgenic alopecia by activating hair follicle stem cells and improving microenvironment conditions, compared to existing minoxidil products.

In this study, topical sildenafil citrate was found to improve hair regeneration in a rat model of androgenic alopecia, showing superior long-term effects compared to minoxidil, including increased hair follicle numbers and epidermal thickness.

This study found that nanostructured lipid carriers significantly improved the targeted delivery of latanoprost and minoxidil to pilosebaceous units in porcine skin, with latanoprost showing notably higher accumulation.

Combining RU58841 and minoxidil significantly increases hair growth.

In this study, men using 2% and 5% minoxidil solutions experienced a significant increase in hair weight for 96 weeks compared to placebo, with effects diminishing after treatment cessation.

This study found that a topical solution combining 0.25% finasteride with 3% minoxidil significantly improved hair growth, as measured by hair density, diameter, and global assessment, in men with androgenetic alopecia, compared to 3% minoxidil alone, over 24 weeks without systemic adverse effects reported.

In this study, finasteride was found to be more effective than 5% minoxidil for treating male androgenetic alopecia in Chinese patients, with combination therapy showing the greatest improvement.

This study found that combining microneedling with topical minoxidil was more effective than minoxidil alone in increasing hair count and improving patient satisfaction for men with androgenetic alopecia, though the cosmetic impact was not significant.

This study observed that 5% minoxidil topical foam alters gene expression and signaling pathways in the scalp, providing insights into its mechanism of action in men with androgenetic alopecia.

A woman developed a scalp condition from using minoxidil, which improved with a different treatment but left scarring.

This study found that combining microneedling with 5% minoxidil improved hair growth in Chinese men with androgenetic alopecia, possibly through activating the Wnt/β-catenin signaling pathway.

In this study, Korean women with female pattern hair loss who used a combination of topical 0.025% 17α-estradiol and 3% minoxidil saw significant increases in total hair count and hair caliber over six months.

This study reported that combined oral finasteride and topical 5% minoxidil treatment in men with male-pattern hair loss improved hair growth by initiating anagen in pre-existing but deficient follicles, yet the growth rates remained unchanged and did not normalize hair productivity.

In this study, topical minoxidil 5% was found to be just as effective as a combination treatment with minoxidil, azelaic acid, and tretinoin for treating androgenetic alopecia.

In this study, combining 2% minoxidil with weekly microneedling significantly improved hair regrowth in women with female pattern hair loss compared to using minoxidil alone, with an 85% effective rate reported in the group receiving both treatments over a 24-week period.

This case report highlights that a patient developed pleural effusion due to unintentional oral use of topical minoxidil, despite not having chronic kidney disease.

The study explored niosome formulations containing minoxidil and tretinoin and found increased drug stability and controlled release, suggesting potential as an effective drug delivery system for treating hair loss.

This study compared microneedling combined with platelet-rich plasma and microneedling with minoxidil for treating androgenetic alopecia in men, finding both approaches effectively improved hair density and alopecia grade.

In this study, the combination of minoxidil, azelaic acid, and tretinoin showed no significant advantage over minoxidil alone for treating androgenetic alopecia.

This study found that using minoxidil 2% as a mesotherapy injection showed more significant improvement in treating androgenetic alopecia in female patients than topical application.

This study aimed to enhance the skin penetration of minoxidil by encapsulating it in glycerosomal vesicles, offering a potential improvement in transdermal drug delivery for treating androgenetic alopecia. Results of the investigation were not reported.

This case report presented by the authors provides the first evidence of severe liver failure associated with the use of topical minoxidil, emphasizing the potential for hepatotoxicity even from drugs with minimal systemic absorption.

Minoxidil rejuvenates hair follicles and reduces aging signs in male pattern baldness.

This study found that combining 17α-estradiol 0.01% with minoxidil 2% offered no statistically significant advantage over minoxidil alone for treating female pattern hair loss and may increase the risk of menstrual irregularities.

This study found that nano-sized molybdenum accelerated hair growth and enhanced the effectiveness of minoxidil in a mouse model by reducing oxidative stress-related molecules.

This study compared the safety and effectiveness of 5% cetosomal minoxidil to 5% alcohol-based minoxidil in Indian men with androgenetic alopecia, finding that cetosomal minoxidil had improved safety and similar efficacy, making it a potentially better option for those sensitive to alcohol-based formulations.

This study found that applying 2% topical minoxidil resulted in a greater nail growth rate compared to 5% minoxidil and placebo over eight weeks, with no observed side effects, suggesting 2% is an effective concentration for accelerating nail growth.